These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
881 related articles for article (PubMed ID: 27177863)
21. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study). Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604 [TBL] [Abstract][Full Text] [Related]
22. Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC). Souglakos J; Ziras N; Kakolyris S; Boukovinas I; Kentepozidis N; Makrantonakis P; Xynogalos S; Christophyllakis Ch; Kouroussis Ch; Vamvakas L; Georgoulias V; Polyzos A Br J Cancer; 2012 Jan; 106(3):453-9. PubMed ID: 22240792 [TBL] [Abstract][Full Text] [Related]
23. A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study. Oki E; Kato T; Bando H; Yoshino T; Muro K; Taniguchi H; Kagawa Y; Yamazaki K; Yamaguchi T; Tsuji A; Iwamoto S; Nakayama G; Emi Y; Touyama T; Nakamura M; Kotaka M; Sakisaka H; Yamanaka T; Kanazawa A Clin Colorectal Cancer; 2018 Jun; 17(2):147-155. PubMed ID: 29530335 [TBL] [Abstract][Full Text] [Related]
24. Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. Cremolini C; Loupakis F; Antoniotti C; Lonardi S; Masi G; Salvatore L; Cortesi E; Tomasello G; Spadi R; Zaniboni A; Tonini G; Barone C; Vitello S; Longarini R; Bonetti A; D'Amico M; Di Donato S; Granetto C; Boni L; Falcone A Ann Oncol; 2015 Jun; 26(6):1188-1194. PubMed ID: 25712456 [TBL] [Abstract][Full Text] [Related]
25. Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study). Moriwaki T; Bando H; Takashima A; Yamazaki K; Esaki T; Yamashita K; Fukunaga M; Miyake Y; Katsumata K; Kato S; Satoh T; Ozeki M; Baba E; Yoshida S; Boku N; Hyodo I Med Oncol; 2012 Dec; 29(4):2842-8. PubMed ID: 22209842 [TBL] [Abstract][Full Text] [Related]
26. S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial. Yamada Y; Denda T; Gamoh M; Iwanaga I; Yuki S; Shimodaira H; Nakamura M; Yamaguchi T; Ohori H; Kobayashi K; Tsuda M; Kobayashi Y; Miyamoto Y; Kotake M; Shimada K; Sato A; Morita S; Takahashi S; Komatsu Y; Ishioka C Ann Oncol; 2018 Mar; 29(3):624-631. PubMed ID: 29293874 [TBL] [Abstract][Full Text] [Related]
27. Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial. Denda T; Takashima A; Gamoh M; Iwanaga I; Komatsu Y; Takahashi M; Nakamura M; Ohori H; Sakashita A; Tsuda M; Kobayashi Y; Baba H; Kotake M; Ishioka C; Yamada Y; Sato A; Yuki S; Morita S; Takahashi S; Yamaguchi T; Shimada K Eur J Cancer; 2021 Sep; 154():296-306. PubMed ID: 34304054 [TBL] [Abstract][Full Text] [Related]
28. TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial. Fuchs CS; Fakih M; Schwartzberg L; Cohn AL; Yee L; Dreisbach L; Kozloff MF; Hei YJ; Galimi F; Pan Y; Haddad V; Hsu CP; Sabin A; Saltz L Cancer; 2013 Dec; 119(24):4290-8. PubMed ID: 24122767 [TBL] [Abstract][Full Text] [Related]
29. Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer. Stein A; Atanackovic D; Hildebrandt B; Stübs P; Brugger W; Hapke G; Steffens CC; Illerhaus G; Bluemner E; Stöhlmacher J; Bokemeyer C Br J Cancer; 2015 Sep; 113(6):872-7. PubMed ID: 26335608 [TBL] [Abstract][Full Text] [Related]
30. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Masi G; Loupakis F; Salvatore L; Fornaro L; Cremolini C; Cupini S; Ciarlo A; Del Monte F; Cortesi E; Amoroso D; Granetto C; Fontanini G; Sensi E; Lupi C; Andreuccetti M; Falcone A Lancet Oncol; 2010 Sep; 11(9):845-52. PubMed ID: 20702138 [TBL] [Abstract][Full Text] [Related]
31. XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions. Uygun K; Bilici A; Kaya S; Oven Ustaalioglu BB; Yildiz R; Temiz S; Seker M; Aksu G; Cabuk D; Gumus M Asian Pac J Cancer Prev; 2013; 14(4):2283-8. PubMed ID: 23725128 [TBL] [Abstract][Full Text] [Related]
32. Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer. Shigeta K; Hasegawa H; Okabayashi K; Tsuruta M; Ishii Y; Endo T; Ochiai H; Kondo T; Kitagawa Y Int J Cancer; 2016 Aug; 139(4):946-54. PubMed ID: 27061810 [TBL] [Abstract][Full Text] [Related]
33. Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial. Carrato A; Swieboda-Sadlej A; Staszewska-Skurczynska M; Lim R; Roman L; Shparyk Y; Bondarenko I; Jonker DJ; Sun Y; De la Cruz JA; Williams JA; Korytowsky B; Christensen JG; Lin X; Tursi JM; Lechuga MJ; Van Cutsem E J Clin Oncol; 2013 Apr; 31(10):1341-7. PubMed ID: 23358972 [TBL] [Abstract][Full Text] [Related]
34. Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial. Passardi A; Nanni O; Tassinari D; Turci D; Cavanna L; Fontana A; Ruscelli S; Mucciarini C; Lorusso V; Ragazzini A; Frassineti GL; Amadori D Ann Oncol; 2015 Jun; 26(6):1201-1207. PubMed ID: 25735317 [TBL] [Abstract][Full Text] [Related]
35. A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases. Chun YJ; Kim SG; Lee KW; Cho SH; Kim TW; Baek JY; Park YS; Hong S; Chu CW; Beom SH; Jung M; Shin SJ; Ahn JB Clin Colorectal Cancer; 2020 Sep; 19(3):e140-e150. PubMed ID: 32402681 [TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Van Cutsem E; Rivera F; Berry S; Kretzschmar A; Michael M; DiBartolomeo M; Mazier MA; Canon JL; Georgoulias V; Peeters M; Bridgewater J; Cunningham D; Ann Oncol; 2009 Nov; 20(11):1842-7. PubMed ID: 19406901 [TBL] [Abstract][Full Text] [Related]
37. Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802). Suenaga M; Nishina T; Mizunuma N; Yasui H; Ura T; Denda T; Ikeda J; Esaki T; Nishisaki H; Takano Y; Sugiyama Y; Muro K BMC Cancer; 2015 Mar; 15():176. PubMed ID: 25884814 [TBL] [Abstract][Full Text] [Related]
38. Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT). Bennouna J; Phelip JM; André T; Asselain B; Sébastien Koné ; Ducreux M Clin Colorectal Cancer; 2017 Jun; 16(2):129-140.e4. PubMed ID: 28277294 [TBL] [Abstract][Full Text] [Related]
39. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961 [TBL] [Abstract][Full Text] [Related]
40. Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. Cremolini C; Antoniotti C; Lonardi S; Aprile G; Bergamo F; Masi G; Grande R; Tonini G; Mescoli C; Cardellino GG; Coltelli L; Salvatore L; Corsi DC; Lupi C; Gemma D; Ronzoni M; Dell'Aquila E; Marmorino F; Di Fabio F; Mancini ML; Marcucci L; Fontanini G; Zagonel V; Boni L; Falcone A JAMA Oncol; 2018 Apr; 4(4):529-536. PubMed ID: 29450468 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]